Adrenoleukodystrophy (ALD) is a rare X-linked disease caused by a mutation of the peroxisomal ABCD1 gene. This review summarizes our current understanding of the pathogenic cell- and tissue-specific roles of lipid species in the context of experimental therapeutic strategies and provides an overview of critical historical developments, therapeutic trials and the advent of newborn screening in the USA. In ALD, very long-chain fatty acid (VLCFA) chain length-dependent dysregulation of endoplasmic reticulum stress and mitochondrial radical generating systems inducing cell death pathways has been shown, providing the rationale for therapeutic moiety-specific VLCFA reduction and antioxidant strategies. The continuing increase in newborn screening programs and promising results from ongoing and recent therapeutic investigations provide hope for ALD.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7041623PMC
http://dx.doi.org/10.1002/jdn.10003DOI Listing

Publication Analysis

Top Keywords

newborn screening
12
x-linked adrenoleukodystrophy
4
adrenoleukodystrophy pathology
4
pathology pathophysiology
4
pathophysiology diagnostic
4
diagnostic testing
4
testing newborn
4
screening therapies
4
therapies adrenoleukodystrophy
4
adrenoleukodystrophy ald
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!